AtriCure (NASDAQ:ATRC) is a medical technology company focused on the treatment of atrial fibrillation (AF) and related left atrial appendage management. The company designs, develops, manufactures and markets surgical ablation devices, adjunctive products and diagnostic tools that support the safe and effective treatment of AF. AtriCure’s product portfolio includes bipolar clamp-based and irrigated radiofrequency ablation systems, cryoablation tools, and a range of stapling and clipping devices intended for left atrial appendage occlusion.
Since its founding in 2000 and subsequent initial public offering in 2005, AtriCure has been committed to advancing the field of surgical electrophysiology through continuous innovation and clinical collaboration. Early investments in research and development led to its signature Isolator Synergy™ Clamp and EPi-Sense® System, which were among the first FDA-cleared devices for surgical AF ablation. Over the years, the company has expanded its technology base by acquiring complementary assets, strengthening its portfolio with products such as cryoICE® cryoablation probes and fabric-encased left atrial appendage occlusion devices.
AtriCure maintains a global commercial footprint, marketing its products in more than 50 countries across North America, Europe, Asia Pacific and Latin America. The company’s U.S. headquarters and primary manufacturing facility are located in Mason, Ohio, with additional sales and support operations in Europe and Asia. AtriCure conducts ongoing clinical studies and collaborates with leading cardiac surgeons and electrophysiologists to validate new techniques and expand the adoption of surgical AF ablation in both stand-alone and hybrid operating room settings.
Leadership at AtriCure is led by President and Chief Executive Officer Michael J. Carrel, who has guided the company’s strategic growth and product development initiatives. Under his stewardship, AtriCure has focused on expanding education programs for clinicians, forging partnerships with healthcare systems and enhancing its post-market surveillance capabilities. The company continues to invest in innovation aimed at improving patient outcomes in AF treatment and strengthening its position within the global cardiac surgery market.
